Agreements

* On November 4, 2013, the non-profit Cancer Research Institute (CRI) and Ludwig Cancer Research, and CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA),will collaborate to enable clinical testing of novel cancer immunotherapy treatment options. 
Ludwig and CRI will conduct up to five clinical studies of cancer immunotherapy combinations through their jointly coordinated CVC Trials Network using CureVac’s investigational clinical stage drug, CV9202, combined with other priority agents available to CRI and Ludwig from their internal portfolios or accessed through additional industry partnerships. CV9202 contains NSCLC-associated antigens and is the optimized successor of CV9201, which has successfully completed a phase I/IIa clinical trial demonstrating its safety and immunogenicity. Additional investigational clinical stage drugs from CureVac’s product pipeline can be added.